SCHEMBL543949

SCHEMBL543949

Fc1ccc(-c2c3ccccc3c(-c3ccc(F)cc3)c3cc(Br)ccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ACHE P22303 1/20 0.44
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43
GABRA1 P14867 2/20 0.43
GABRB1 P18505 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRA4 P48169 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13241716 0.88 ALDH1A1 (0.46) CYP1A2CYP3A4CYP2C19KDM4EHPGD
SCHEMBL12791336 0.85 ALDH1A1 (0.54) KDM4EL3MBTL1ACHEGABRPGABRD
SCHEMBL28924402 0.85 ALDH1A1 (0.54) KDM4EL3MBTL1ACHEGABRPGABRD
SCHEMBL2712765 0.84 ACHE (0.49) CYP1A2CYP3A4CYP2C19KDM4EHPGD
SCHEMBL389776 0.84 ALDH1A1 (0.46) KDM4EL3MBTL1ACHEGABRPGABRD
SCHEMBL30136959 0.84 ALDH1A1 (0.46) KDM4EL3MBTL1ACHEGABRPGABRD
SCHEMBL4584724 0.82 ALDH1A1 (0.48) KDM4EL3MBTL1GABRPGABRDGABRA1
SCHEMBL824275 0.82 ALDH1A1 (0.48) KDM4EL3MBTL1GABRPGABRDGABRA1
SCHEMBL5555772 0.80 CYP1A2 (0.56) CYP1A2CYP3A4CYP2C19KDM4EHPGD
SCHEMBL13158728 0.79 ACHE (0.49) CYP1A2CYP3A4CYP2C19KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
EP-1918350-B1 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LAB (JP) 2010-08-11 EP disclosed
EP-1918350-B1 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LAB (JP) 2010-08-11 EP disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
EP-1918350-A2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-07 EP disclosed
EP-1918350-A2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-07 EP disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 CYP1A2 19/4885CYP3A4 222/4885CYP2C19 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.